tiprankstipranks
Advertisement
Advertisement

RLAY Stock Latest News

Relay Therapeutics price target raised to $25 from $19 at H.C. Wainwright
The FlyRelay Therapeutics price target raised to $25 from $19 at H.C. Wainwright
6d ago
RLAY
Relay Therapeutics price target raised to $18 from $14 at Oppenheimer
PremiumThe Fly
Relay Therapeutics price target raised to $18 from $14 at Oppenheimer
7d ago
RLAY
Relay Therapeutics price target raised to $21 from $17 at Wells Fargo
PremiumThe Fly
Relay Therapeutics price target raised to $21 from $17 at Wells Fargo
7d ago
RLAY
Relay Therapeutics price target raised to $22 from $13 at Goldman Sachs
PremiumThe Fly
Relay Therapeutics price target raised to $22 from $13 at Goldman Sachs
7d ago
RLAY
Relay Therapeutics price target raised to $19 from $17 at Citizens
PremiumThe Fly
Relay Therapeutics price target raised to $19 from $17 at Citizens
7d ago
RLAY
Analyst Reiterates Buy on Relay Therapeutics, Citing Promising Zovega mBC Data, Favorable Safety Profile, and Phase 3 First-Line Breast Cancer Upside
PremiumRatingsAnalyst Reiterates Buy on Relay Therapeutics, Citing Promising Zovega mBC Data, Favorable Safety Profile, and Phase 3 First-Line Breast Cancer Upside
7d ago
RLAY
Relay Therapeutics advances zovegalisib combo in breast cancer
Premium
Company Announcements
Relay Therapeutics advances zovegalisib combo in breast cancer
8d ago
8K
RLAY
Relay Therapeutics’ combination for breast cancer shows efficacy and safetyPfizer
Premium
The Fly
Relay Therapeutics’ combination for breast cancer shows efficacy and safetyPfizer
8d ago
PFE
RLAY
Relay Therapeutics initiated with a Hold at JonesResearch
PremiumThe Fly
Relay Therapeutics initiated with a Hold at JonesResearch
22d ago
RLAY
Relay Therapeutics price target raised to $21 from $17 at Barclays
PremiumThe Fly
Relay Therapeutics price target raised to $21 from $17 at Barclays
27d ago
RLAY
Relay Therapeutics price target raised to $19 from $14 at H.C. Wainwright
PremiumThe Fly
Relay Therapeutics price target raised to $19 from $14 at H.C. Wainwright
1M ago
RLAY
Relay Therapeutics: Encouraging Zovegalisib Phase 3 Prospects, Strong Cash Runway, and Raised Price Target Support Buy Rating
PremiumRatings
Relay Therapeutics: Encouraging Zovegalisib Phase 3 Prospects, Strong Cash Runway, and Raised Price Target Support Buy Rating
1M ago
RLAY
Relay Therapeutics price target raised to $17 from $15 at Citizens
PremiumThe FlyRelay Therapeutics price target raised to $17 from $15 at Citizens
2M ago
RLAY
Relay Therapeutics Highlights Positive Zovegalisib ReDiscover Trial Data
Premium
Company Announcements
Relay Therapeutics Highlights Positive Zovegalisib ReDiscover Trial Data
2M ago
8K
RLAY
Relay Therapeutics announces data from Phase 1/2 ReDiscover trial
Premium
The Fly
Relay Therapeutics announces data from Phase 1/2 ReDiscover trial
2M ago
RLAY
Relay Therapeutics price target raised to $22 from $15 at Guggenheim
PremiumThe Fly
Relay Therapeutics price target raised to $22 from $15 at Guggenheim
2M ago
NVS
RLAY
Relay Therapeutics Updates Bylaws on Federal Securities Litigation
PremiumCompany Announcements
Relay Therapeutics Updates Bylaws on Federal Securities Litigation
2M ago
8K
RLAY
Relay Therapeutics reports Q4 EPS (32c), consensus (39c)
PremiumThe Fly
Relay Therapeutics reports Q4 EPS (32c), consensus (39c)
2M ago
RLAY
RLAY Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
RLAY Upcoming Earnings Report: What to Expect?
3M ago
RLAY
Relay Therapeutics Wins FDA Breakthrough Therapy Designation
PremiumCompany AnnouncementsRelay Therapeutics Wins FDA Breakthrough Therapy Designation
3M ago
8K
RLAY
Relay Therapeutics announces U.S. FDA granted BTD to zovegalisib
Premium
The Fly
Relay Therapeutics announces U.S. FDA granted BTD to zovegalisib
3M ago
RLAY
Relay Therapeutics upgraded at Oppenheimer ahead of VIKTORIA-1 readout
Premium
The Fly
Relay Therapeutics upgraded at Oppenheimer ahead of VIKTORIA-1 readout
3M ago
RLAY

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >